Stemline names Eric Rowinsky CMO
This article was originally published in Scrip
Stemline Therapeutics, a biopharma company developing novel oncology therapeutics that target cancer stem cells, has appointed Dr Eric Rowinsky executive vice-president, chief medical officer and head of R&D. Dr Rowinsky has more than 25 years' experience managing clinical trials and developing drugs from preclinical to regulatory approval, having previously served as executive vice-president and CMO for Imclone Systems where he led the FDA approval of Erbitux (cetuximab).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.